

# Charles A Schiffer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9186742/publications.pdf>

Version: 2024-02-01

112  
papers

16,559  
citations

126708

33  
h-index

33814

99  
g-index

114  
all docs

114  
docs citations

114  
times ranked

11474  
citing authors

#	ARTICLE	IF	CITATIONS
1	Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2003, 21, 4642-4649.	0.8	2,425
2	Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B. <i>Journal of Clinical Oncology</i> , 2002, 20, 2429-2440.	0.8	1,735
3	Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). <i>Blood</i> , 2002, 100, 4325-4336.	0.6	1,444
4	Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. <i>Blood</i> , 2006, 108, 419-425.	0.6	1,395
5	Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 1994, 331, 896-903.	13.9	1,328
6	Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. <i>Blood</i> , 2002, 99, 3530-3539.	0.6	1,096
7	Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. <i>Blood</i> , 2002, 99, 1928-1937.	0.6	943
8	2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines. <i>Journal of Clinical Oncology</i> , 2000, 18, 3558-3585.	0.8	761
9	Platelet Transfusion for Patients With Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology*. <i>Journal of Clinical Oncology</i> , 2001, 19, 1519-1538.	0.8	546
10	A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. <i>Blood</i> , 2002, 100, 1965-1971.	0.6	534
11	Acute myeloid leukaemia in adults. <i>Lancet</i> , The, 2013, 381, 484-495.	6.3	470
12	Randomized Trial of a Slow-Release Versus a Standard Formulation of Cytarabine for the Intrathecal Treatment of Lymphomatous Meningitis. <i>Journal of Clinical Oncology</i> , 1999, 17, 3110-3116.	0.8	393
13	Differentiation of Leukemia Cells to Polymorphonuclear Leukocytes in Patients with Acute Nonlymphocytic Leukemia. <i>New England Journal of Medicine</i> , 1986, 315, 15-24.	13.9	296
14	Patients With t(8;21)(q22;q22) and Acute Myeloid Leukemia Have Superior Failure-Free and Overall Survival When Repetitive Cycles of High-Dose Cytarabine Are Administered. <i>Journal of Clinical Oncology</i> , 1999, 17, 3767-3775.	0.8	290
15	Central Venous Catheter Care for the Patient With Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2013, 31, 1357-1370.	0.8	278
16	Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2018, 36, 283-299.	0.8	217
17	Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. <i>Blood</i> , 2001, 98, 548-553.	0.6	197
18	Improved prognosis for granulocytopenic patients with gram-negative bacteremia. <i>American Journal of Medicine</i> , 1980, 68, 643-648.	0.6	196

#	ARTICLE	IF	CITATIONS
19	BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia. <i>New England Journal of Medicine</i> , 2007, 357, 258-265.	13.9	169
20	Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180034. <i>American Journal of Hematology</i> , 2016, 91, 869-874.	2.0	145
21	Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. <i>Blood</i> , 2008, 111, 1774-1780.	0.6	140
22	Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. <i>Blood</i> , 2005, 105, 3420-3427.	0.6	125
23	Quality of life for adult leukemia survivors treated on clinical trials of cancer and leukemia group B during the period 1971-1988. , 1997, 80, 1936-1944.		113
24	Lymphocytotoxic antibody is a predictor of response to random donor platelet transfusion. <i>American Journal of Hematology</i> , 1983, 14, 363-369.	2.0	93
25	White cell reduction in platelet concentrates and packed red cells by filtration: a multicenter clinical trial. The Trap Study Group. <i>Transfusion</i> , 1995, 35, 13-19.	0.8	86
26	Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw003.	3.0	82
27	Acute promyelocytic leukemia—clinical management of 15 patients. <i>American Journal of Hematology</i> , 1980, 8, 347-359.	2.0	63
28	Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia. <i>JAMA Oncology</i> , 2021, 7, 42.	3.4	51
29	Granulocyte transfusion therapy and amphotericin B: Adverse reactions?. <i>American Journal of Hematology</i> , 1989, 31, 102-108.	2.0	50
30	Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity. <i>Cancer</i> , 2016, 122, 1398-1407.	2.0	47
31	Incidence of thrombocytopenia and serious hemorrhage among patients with solid tumors. <i>Cancer</i> , 1984, 53, 557-562.	2.0	46
32	Promyelocytic blast crisis in chronic granulocytic leukemia with 15;17 translocation. <i>Leukemia Research</i> , 1984, 8, 1019-1023.	0.4	44
33	Phase 2 study of ibrutinib in classic and variant hairy cell leukemia. <i>Blood</i> , 2021, 137, 3473-3483.	0.6	40
34	Granulocyte transfusion therapy 2006: The comeback kid?. <i>Medical Mycology</i> , 2006, 44, 383-386.	0.3	33
35	“œl Am Older, Not Elderly,” Said the Patient With Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 521-523.	0.8	33
36	Hematopoietic Growth Factors and the Future of Therapeutic Research on Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2003, 349, 727-729.	13.9	29

#	ARTICLE	IF	CITATIONS
37	Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?. <i>Haematologica</i> , 2020, 105, 2738-2745.	1.7	28
38	Chemotherapy-induced lactose intolerance in adults. <i>Cancer</i> , 1994, 74, 1629-1633.	2.0	27
39	Very late recurrences of leukemia: Why does leukemia awake after many years of dormancy?. <i>Leukemia Research</i> , 2011, 35, 139-144.	0.4	27
40	Should All Platelet Concentrates Issued Be Leukocyteâ€Poor?. <i>Vox Sanguinis</i> , 1992, 62, 57-64.	0.7	26
41	Bronchoscopy can be done safely in patients with thrombocytopenia. <i>Transfusion</i> , 2016, 56, 344-348.	0.8	25
42	Prevalence of large granular lymphocytosis in patients with chronic myelogenous leukemia (CML) treated with dasatinib. <i>Leukemia Research</i> , 2011, 35, e1-e3.	0.4	24
43	Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal. <i>EBioMedicine</i> , 2017, 26, 17-24.	2.7	24
44	Acute myeloid leukemia in adults: where do we go from here?. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 48, S45-S52.	1.1	22
45	Realâ€world testing and treatment patterns in chronic lymphocytic leukemia: A SEER patterns of care analysis. <i>Cancer</i> , 2019, 125, 135-143.	2.0	20
46	Philadelphia chromosome-positive acute leukemia: Morphologic and clinical correlations. <i>American Journal of Hematology</i> , 1987, 25, 311-324.	2.0	18
47	World Health Organization and International Prognostic Scoring System: The Limitations of Current Classification Systems in Assessing Prognosis and Determining Appropriate Therapy in Myelodysplastic Syndromes. <i>Seminars in Hematology</i> , 2008, 45, 3-7.	1.8	18
48	Exploring Patient Decision Making Regarding Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia. <i>Oncologist</i> , 2019, 24, 1253-1258.	1.9	16
49	Clinical Issues in the Management of Patients with Myelodysplasia. <i>Hematology American Society of Hematology Education Program</i> , 2006, 2006, 205-210.	0.9	16
50	Clinical and cytogenetic features of familial erythroleukaemia. <i>British Journal of Haematology</i> , 1987, 65, 313-320.	1.2	15
51	Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. <i>BMC Cancer</i> , 2018, 18, 359.	1.1	15
52	Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary. <i>Journal of Oncology Practice</i> , 2018, 14, 129-133.	2.5	14
53	â€Acute myelogenous leukemia likeâ€translocations in CML blast crisis: Two new cases of inv(16)/t(16;16) and a review of the literature. <i>Leukemia Research</i> , 2006, 30, 225-232.	0.4	13
54	Effect of histocompatibility factors on pulmonary retention of indium-111-labeled granulocytes. <i>American Journal of Hematology</i> , 1990, 33, 238-243.	2.0	12

#	ARTICLE	IF	CITATIONS
55	Concurrent B-cell chronic lymphocytic leukemia and multiple myeloma treated successfully with lenalidomide. <i>Leukemia Research</i> , 2009, 33, 561-564.	0.4	12
56	Prophylactic platelet transfusion is frequently not necessary. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 431-432.	12.5	11
57	Use of "Split"™ Plateletpheresis Products for Alloimmunized Patients. <i>Vox Sanguinis</i> , 1994, 67, 272-274.	0.7	10
58	Divide and conquer: stomping leukemia cells by stimulating them to grow. <i>Blood</i> , 2005, 106, 3-4.	0.6	10
59	What to do if there is no evidence? The issue of surgical procedures in patients with thrombocytopenia. <i>Transfusion</i> , 2011, 51, 2262-2264.	0.8	10
60	An Important Gap in Informed Consent Documents for Oncology Clinical Trials. <i>JAMA Oncology</i> , 2019, 5, 1399.	3.4	10
61	Long Term Clinical Benefit of Lenalidomide (Revlimid) Treatment in Patients with Myelodysplastic Syndrome without Del 5q Cytogenetic Abnormalities.. <i>Blood</i> , 2006, 108, 250-250.	0.6	10
62	Lymphocytosis Following First-Line Treatment for CML In Chronic Phase with Dasatinib Is Associated with Improved Responses: A Comparison with Imatinib. <i>Blood</i> , 2010, 116, 358-358.	0.6	10
63	Infectious Complications of Tyrosine Kinase Inhibitors in Hematological Malignancies. <i>Infectious Disease Clinics of North America</i> , 2020, 34, 245-256.	1.9	9
64	Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors. <i>Journal of the National Cancer Institute</i> , 2022, 114, 160-164.	3.0	9
65	Weekly Inotuzumab Ozogamicin (InO) In Adult Patients With Relapsed Or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2013, 122, 3906-3906.	0.6	9
66	The Significance of Abnormal Circulating Cells in Patients with Hodgkin's Disease. <i>British Journal of Haematology</i> , 1975, 31, 177-183.	1.2	8
67	Optimal dose and schedule of consolidation in AML: Is there a standard?. <i>Best Practice and Research in Clinical Haematology</i> , 2014, 27, 259-264.	0.7	8
68	Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia. <i>Biologics: Targets and Therapy</i> , 2009, 3, 205-14.	3.0	8
69	Molecular characterization of AML: A significant advance or just another prognostic factor?. <i>Best Practice and Research in Clinical Haematology</i> , 2008, 21, 621-628.	0.7	7
70	The spectrum of musculoskeletal symptoms in patients with chronic myeloid leukemia after stopping tyrosine kinase inhibitors. <i>Leukemia Research</i> , 2019, 79, 1-2.	0.4	7
71	Outcome By Mutation Status and Line of Treatment in Optic, a Dose-Ranging Study of 3 Starting Doses of Ponatinib in Patients with CP-CML. <i>Blood</i> , 2020, 136, 44-45.	0.6	7
72	Myelodysplasia: The good, the fair and the ugly. <i>Best Practice and Research in Clinical Haematology</i> , 2007, 20, 49-55.	0.7	6

#	ARTICLE	IF	CITATIONS
73	CML: how low can you go?. <i>Blood</i> , 2010, 116, 3686-3687.	0.6	6
74	They took a mulligan and mostly got it right – the issue of prophylactic platelet transfusion for patients receiving autologous stem cell transplantation. <i>Transfusion</i> , 2014, 54, 2372-2374.	0.8	6
75	What Is the Most Cost-Effective Strategy for Treating Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) after Imatinib Loses Patent Exclusivity?. <i>Blood</i> , 2014, 124, 738-738.	0.6	6
76	Transplantation for Myeloma – Now or Later?. <i>New England Journal of Medicine</i> , 2017, 376, 1378-1379.	13.9	5
77	The evolution of dasatinib dosage over the years and its relevance to other anticancer medications. <i>Cancer</i> , 2018, 124, 2687-2689.	2.0	5
78	The costs of treating and not treating patients with chronic myeloid leukemia with tyrosine kinase inhibitors among Medicare patients in the United States. <i>Cancer</i> , 2021, 127, 93-102.	2.0	5
79	Expression of the Neural Cell Adhesion Molecule CD56 Is Associated With Short Remission Duration and Survival in Acute Myeloid Leukemia With t(8; 21)(q22; q22). <i>Blood</i> , 1997, 90, 1643-1648.	0.6	5
80	ReCAP: Pattern of Duplicate Presentations at National Hematology-Oncology Meetings: Influence of the Pharmaceutical Industry. <i>Journal of Oncology Practice</i> , 2016, 12, 252-253.	2.5	4
81	To what extent can mathematical modeling inform the design of clinical trials? The example of safe dose reduction of tyrosine kinase inhibitors in responding patients with chronic myeloid leukemia. <i>Haematologica</i> , 2018, 103, 1756-1757.	1.7	4
82	Promoting Apoptosis with Venetoclax – A Benefit for Older Patients with AML. <i>New England Journal of Medicine</i> , 2020, 383, 677-679.	13.9	4
83	Granulocyte transfusions in haematopoietic cell transplants and leukaemia: the phoenix or beating a dead horse?. <i>Bone Marrow Transplantation</i> , 2021, 56, 2046-2049.	1.3	4
84	How to Effectively Decrease Patient Co-Payments of High-Cost Drugs Through Innovation: Lessons From the Karmanos Specialty Pharmacy. <i>JCO Oncology Practice</i> , 2022, 18, e137-e151.	1.4	4
85	Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia. <i>Haematologica</i> , 2022, 107, 2641-2649.	1.7	4
86	Current treatment options and strategies for myelodysplastic syndromes. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 1667-1678.	0.9	3
87	Molecular Monitoring of BCR-ABL Transcripts in Patients With Chronic Myelogenous Leukemia: Is High Sensitivity of Clinical Value?. <i>Current Hematologic Malignancy Reports</i> , 2010, 5, 88-94.	1.2	3
88	–Epigenetic–modification as therapy for acute myeloid leukemia. <i>Cancer</i> , 2018, 124, 242-244.	2.0	3
89	Combined Treatment with Lenalidomide and Epoetin Alfa Leads to Durable Responses in Patients with Epo-Refractory, Lower Risk Non-Deletion 5q [Del(5q)] MDS: Final Results of the E2905 Intergroup Phase III Study - an ECOG-ACRIN Cancer Research Group Study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health. <i>Blood</i> , 2019, 134, 842-842.	0.6	3
90	Seven-Year (yr) Follow-up of Patients (pts) with Imatinib-Resistant or -Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Receiving Dasatinib in Study CA180-034, Final Study Results. <i>Blood</i> , 2014, 124, 520-520.	0.6	3

#	ARTICLE	IF	CITATIONS
91	Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia. <i>Blood</i> , 2019, 134, 705-705.	0.6	3
92	Asciminib for CML: same target, new arrow. <i>Blood</i> , 2021, 138, 2009-2010.	0.6	3
93	Monitoring minimal residual disease in patients with chronic myeloid leukemia after treatment with tyrosine kinase inhibitors. <i>Current Opinion in Hematology</i> , 2008, 15, 134-139.	1.2	2
94	Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia. <i>Biologics: Targets and Therapy</i> , 0, , 205.	3.0	2
95	Diagnosis and Treatment of Chronic Myeloid Leukemia. , 2018, , 49-68.		2
96	Discontinuation of tyrosine kinase inhibitors in patients with chronic myelogenous leukemia â€œ You can do this at home if you read the instructions. <i>Haematologica</i> , 2019, 104, 1508-1511.	1.7	2
97	Commentary on the prescient observations made by Emil J Freireich in <i>Effectiveness of platelet transfusion in leukemia and aplastic anemia</i> ( <i>Transfusion</i> 1966; 6: 50â€œ54). <i>Transfusion</i> , 2022, 62, 267-272.	0.8	2
98	If at First You Don't Succeed: Stem-Cell Transplantation for Acute Myeloid Leukemia After First Relapse. <i>Journal of Clinical Oncology</i> , 2013, 31, 1259-1261.	0.8	1
99	Which TKI should be recommended as initial treatment for CML in chronic phase?. <i>Oncology</i> , 2012, 26, 912, 914.	0.4	1
100	First-line treatment for patients with CML in chronic phase: why imatinib is an appropriate choice. <i>Oncology</i> , 2013, 27, 780, 825.	0.4	1
101	Racial disparities in time to hematopoietic cell transplant among patients with hematologic malignancies at a large urban academic center. <i>Bone Marrow Transplantation</i> , 2022, 57, 1213-1215.	1.3	1
102	Opportunities for the use of thrombopoietic growth factors. <i>Stem Cells</i> , 1998, 16, 249-253.	1.4	0
103	Haematologic Cancers. , 0, , 141-148.		0
104	Use of myeloid growth factors for patients with febrile neutropenia: Plus Ã¢ Change, Plus C'est La MÃ¢me Chose. <i>Pediatric Blood and Cancer</i> , 2005, 45, 242-243.	0.8	0
105	Should all adults with acute lymphocytic leukemia receive allogeneic stem cell transplantation in first remission?. <i>International Journal of Hematologic Oncology</i> , 2014, 3, 325-334.	0.7	0
106	Inhibition of Multiple Myeloma Cell Adhesion to Fibronectin by Ephrin Ligation.. <i>Blood</i> , 2004, 104, 2360-2360.	0.6	0
107	Severe Thrombocytopenia Does Not Increase Bleeding Complications in Patients Undergoing Bronchoscopy. <i>Blood</i> , 2014, 124, 4293-4293.	0.6	0
108	Supportive Care for Patients with Leukemia: A Historical Perspective. , 2018, , 1039-1045.		0

#	ARTICLE	IF	CITATIONS
109	"3+7" therapy for the treatment of acute myeloid leukemia. PRO. Clinical Advances in Hematology and Oncology, 2005, 3, 127-9.	0.3	0
110	Advances in MDS. Clinical Advances in Hematology and Oncology, 2007, 5, 450-2.	0.3	0
111	Haematologic Cancers: Challenges in Developing New Therapeutic Approaches. , 0, , 167-175.		0
112	An evaluation of ponatinib as a therapy in adult patients with resistant/intolerant chronic-phase chronic myeloid leukemia. Expert Review of Hematology, 2022, 15, 393-402.	1.0	0